CN110526985A - A kind of Chimeric antigen receptor of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application - Google Patents
A kind of Chimeric antigen receptor of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application Download PDFInfo
- Publication number
- CN110526985A CN110526985A CN201810513550.1A CN201810513550A CN110526985A CN 110526985 A CN110526985 A CN 110526985A CN 201810513550 A CN201810513550 A CN 201810513550A CN 110526985 A CN110526985 A CN 110526985A
- Authority
- CN
- China
- Prior art keywords
- egfr
- cell
- chimeric antigen
- antigen receptor
- car
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15041—Use of virus, viral particle or viral elements as a vector
- C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Virology (AREA)
- Public Health (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Chimeric antigen receptor CAR-EGFR, the CAR-EGFR the present invention provides a kind of targeting EGFR include the amino acid sequence as shown in SEQ ID NO:1.The present invention also provides a kind of Chimeric antigen receptor T cells including the CAR-EGFR, the Chimeric antigen receptor CAR-EGFR of the targeting EGFR can be with the targeting EGFR positive tumor cell of specificity, it activates T cell to play immunization of cell and realizes killing efficient to EGFR positive tumor cell and specific, with lasting cell viability and lethality, and damage is not will cause to normal cell.The present invention also provides a kind of preparation method and application of the Chimeric antigen receptor T cell of targeting EGFR.
Description
Technical field
The present invention relates to field of medical biotechnology, in particular to a kind of Chimeric antigen receptor of targeting EGFR, chimeric antigen by
Body T cell and its preparation method and application.
Background technique
Prevention and control of cancer difficulty is big, Disease Spectrum weight, it has also become seriously endanger human health great public health problem it
One.EGF-R ELISA (epidermal growth factor receptor, EGFR) is epidermal growth factor (EGF)
The receptor of cell Proliferation and signal transduction belongs to one kind of tyrosine kinase I receptor subfamily.Studies have shown that in many realities
High expression or unconventionality expression in body tumour there are EGFR.The proliferation of EGFR and tumour cell, tumor invasion, turns angiogenesis
It moves and the inhibition of Apoptosis is related.Therefore in oncotherapy, EGFR can become a very important medication target spot.
Chimeric antigen receptor T cell technology (Chimeric Antigen Receptor-Modified T Cells, CAR-
T) as one of current newest immunocyte technology, because it can activate self immune system in vivo, routinely target
It is killed to tumour cell, is finally reached fully erased malignant cell, is widely paid close attention to and studied.But
The current application of CART technology is also limited to blood tumor, does not have correlative study also for the application of a variety of EGFR positive solid tumors.
Summary of the invention
To solve the above problems, the present invention provides the Chimeric antigen receptor CAR-EGFR and target of a kind of targeting EGFR
To the Chimeric antigen receptor T cell of EGFR.The Chimeric antigen receptor CAR-EGFR of the targeting EGFR can be with the targeting of specificity
EGFR positive tumor cell, activation T cell play immunization of cell and realize and specificity efficient to EGFR positive tumor cell
Killing, there is lasting cell viability and lethality, and not will cause damage to normal cell.The present invention also provides one
The preparation method and application of the Chimeric antigen receptor T cell of kind targeting EGFR.
In a first aspect, the present invention provides the Chimeric antigen receptor CAR-EGFR, the CAR-EGFR of a kind of targeting EGFR
Including the amino acid sequence as shown in SEQ ID NO:1.
Optionally, the encoding gene of the Chimeric antigen receptor CAR-EGFR of the targeting EGFR includes such as SEQ ID NO:2
Shown in nucleotide sequence.
Optionally, the Chimeric antigen receptor encoding gene of the targeting EGFR should consider degeneracy base, i.e., such as SEQ ID
The encoding gene of amino acid sequence shown in NO:1 includes the nucleotide sequence as shown in SEQ ID NO:2, and protection scope is also answered
The protection and SEQ ID NO:2 have the nucleotide sequence of base degeneracy matter, the corresponding amino acid sequence of these nucleotide sequences
Column remain as SEQ ID NO:1.
First aspect present invention provide the CAR-EGFR can specific recognition EGFR antigen protein, with EGFR antigen
Albumen is specifically bound, and has stronger affine activity to the solid tumor cell of tumour cell, especially expression EGFR.
Second aspect, the present invention provides a kind of Chimeric antigen receptor T cells of targeting EGFR, including the embedding of targeting EGFR
Antigen receptor CAR-EGFR is closed, the CAR-EGFR includes the amino acid sequence as shown in SEQ ID NO:1.
Optionally, the amino acid sequence of the CAR-EGFR includes the nucleotide sequence as shown in SEQ ID NO:2.
Optionally, the Chimeric antigen receptor CAR-EGFR of the targeting EGFR includes intracellular signal area；The intracellular signal
Area includes 4-1BB signaling zone and CD3 ζ signaling zone.Heretofore described intracellular signal area is used to provide the signal of T cell activation,
Maintain the life span and activation T cell proliferation signal access of T cell.
The Chimeric antigen receptor T cell of targeting EGFR of the present invention can include neuroglia with efficient identification and killing
The expression such as tumor, cancer of pancreas and lung cancer have the cancer cell of EGFR；It is suitable for the solid tumor cell or tissue of the EGFR positive simultaneously.Due to
There is expression, therefore, the Chimeric antigen receptor T of herein described targeting EGFR in a variety of cancer cells or tumour cell in EGFR
Cell it is applied widely, a variety of EGFR positive tumor cells can be killed.
The Chimeric antigen receptor T cell for the targeting EGFR that second aspect of the present invention provides, including the embedding of targeting EGFR
Close antigen receptor CAR-EGFR, this receptor for T cell targeted expression EGFR in specific manner tumour cell, in CAR-
After EGFR is in conjunction with EGFR, the intracellular signal area of the T cell is activated, and promotes T cell in the amplification of patient's body, and efficiently
And the killing tumor cell of specificity, and normal cell is hardly caused to damage, to reach removing tumour cell, realize
Antitumor purpose.
The third aspect, the present invention provides a kind of recombinant viral vector, the recombinant viral vector includes such as first aspect
The CAR-EGFR or as described in second aspect the CAR-EGFR of the Chimeric antigen receptor T cell of targeting EGFR encoding gene.
Optionally, the encoding gene of the CAR-EGFR includes the nucleotide sequence as shown in SEQ ID NO:3.
Optionally, the viral vectors in the recombinant viral vector includes slow virus carrier, adenovirus vector or reverse transcription
Viral vectors.
Still optionally further, the viral vectors is slow virus carrier.Further optionally, the slow virus carrier packet
Include at least one of pWPXLD carrier, pLEX-MCS carrier, pSico carrier and pCgpV carrier.
The recombinant viral vector that third aspect present invention provides is a safe and reliable carrier tool, can efficiently be turned
Move the encoding gene of the CAR-EGFR；The recombinant viral vector can be used for preparing the coding base for carrying the CAR-EGFR
The virus of cause.The recombinant viral vector can be also used for the preparation of the Chimeric antigen receptor T cell of targeting EGFR, make the T
The expression of cell realization height tissue specificity.
Fourth aspect, the present invention provides a kind of host cell, the host cell includes the weight as described in the third aspect
Group viral vectors.
Optionally, the host cell may include HEK293T cell, 293 cells, 293T cell, 293FT cell,
SW480 cell, u87MG cell, HOS cell, COS1 cell or COS7 cell etc., but not limited to this.
Still optionally further, the host cell is HEK293T cell.
The host cell that fourth aspect present invention provides is used to provide and carries the recombinant virus as described in the third aspect
The assembling of body simultaneously prepares the place for generating corresponding virus, and the heredity of the CAR-EGFR is carried by virus prepared by host cell
Information has strong infectivity.
5th aspect, the present invention provides a kind of preparation methods of the Chimeric antigen receptor T cell of targeting EGFR, comprising:
(1) encoding gene of the Chimeric antigen receptor CAR-EGFR of targeting EGFR, the coding base of the CAR-EGFR are provided
Because including nucleotide sequence corresponding to the amino acid sequence as shown in SEQ ID NO:1；
(2) encoding gene of the CAR-EGFR is inserted into pWPXLD carrier, obtains pWPXLD-CAR-EGFR recombination
Plasmid；
(3) it by the pWPXLD-CAR-EGFR recombinant plasmid and envelope plasmid, packaging plasmid cotransfection host cell, obtains
To recombinant slow virus；
(4) recombinant slow virus is infected into CD3 positive t lymphocytes；
(5) separate and obtain the Chimeric antigen receptor T cell of targeting EGFR.
Optionally, the encoding gene of the CAR-EGFR includes the nucleotide sequence as shown in SEQ ID NO:3.Accordingly
Ground, the amino acid sequence of the CAR-EGFR is as shown in SEQ ID NO:4.
It include the encoding gene of a signal peptide in the encoding gene of CAR-EGFR of the present invention；The signal peptide is for referring to
The Chimeric antigen receptor CAR-EGFR expression is led to cell surface, the signal peptide is in protein translation maturation by signal
Peptase cutting.
Optionally, the amino acid sequence of the signal peptide includes the amino acid sequence as shown in SEQ ID NO:5.
Optionally, the encoding gene of the signal peptide includes the nucleotide sequence as shown in SEQ ID NO:6.
Optionally, the encoding gene of the signal peptide should consider degeneracy base, the i.e. amino as shown in SEQ ID NO:5
The encoding gene of acid sequence includes the nucleotide sequence as shown in SEQ ID NO:6, and protection scope should also be protected and SEQ ID
NO:6 has the nucleotide sequence of base degeneracy matter, and the corresponding amino acid sequence of these nucleotide sequences remains as SEQ ID
NO:5。
Optionally, the encoding gene of the CAR-EGFR be inserted into pWPXLD carrier BamH I and I restriction enzyme site of EcoR it
Between, and be located at after the EF1 α of pWPXLD carrier, using EF1 α as promoter.The encoding gene of the CAR-EGFR is inserted into
When pWPXLD carrier, initiation codon (such as ATG) and pWPXLD carrier can be added in 5 ' ends of the encoding gene of the CAR-EGFR
Middle I restriction enzyme site of BamH is connected, and terminator codon (such as TAA) and I restriction enzyme site phase of EcoR in pWPXLD carrier can be added in 3 ' ends
Even.
Optionally, the envelope plasmid is PMD2G, and the packaging plasmid is psPAX2, and the host cell is HEK293T
Cell.
The envelope plasmid PMD2G encodes vesicular stomatitis virus glycoprotein capsid, the vesicular stomatitis virus sugar egg
White capsid assists recombinant slow virus to adhere to cell membrane, and keeps the infectivity of recombinant slow virus.
Recombinant slow virus of the present invention can further contain the envelope protein from other viruses.For example, as this
Kind protein, is preferably the virus enveloped protein for carrying out self-infection human cell.To this protein, there is no particular limitation, can example
The amphophilic virus hand epithelium albumen etc. for enumerating retrovirus, can be used for example from mouse leukemia virus (MuMLV)
4070A plants of envelope protein.Alternatively, it is also possible to use the envelope protein from MuMLV 10Al.In addition, as herpetoviridae
Albumen, it can be cited for example that, gB, gD, gH, gp85 albumen of herpes simplex virus, gp350, gp220 albumen of Epstein-Barr virus
Deng.As the albumen of Hepadna Virus section, the S protein etc. of hepatitis B virus can be included.
The packaging of recombinant slow virus is generallyd use transient transfection or is packed using cell line.It may be used as wrapping when transient transfection
Human cell's strain that dress cell uses, for example including 293 cells, 293T cell, 293FT cell, 293LTV cell, 293EBNA
Cell and other clones separated from 293 cells；SW480 cell, u87MG cell, HOS cell, C8166 cell, MT-4 are thin
Born of the same parents, Molt-4 cell, Hela cell, HT1080 cell, TE671 cell etc..It can also be using the cell strain from monkey, example
Such as, COS1 cell, COS7 cell, CV-1 cell, BMT10 cell etc..Moreover, the calcium phosphate and PEI transfection reagent that generally use,
It is also well used there are also some transfection reagents such as Lipofectamine2000, FuGENE and S93fectin.
The packaging of recombinant slow virus also uses some slow virus package cell lines, such as most common Env glycoprotein of use,
Stable cell lines caused by VSVG albumen or HIV-1gag-pol albumen.
For the sake of security, the slow virus carrier system of large-scale use is all the method using split gene group, i.e., will
The assignment of genes gene mapping of different miscellaneous functions is played in different plasmids.There are four pUC pUCs (encoding gag-pol gene, Rev base at present
Cause, VSVG gene, SIN metastatic gene be located at four different plasmids), three pUC pUCs (eliminate coding Rev gene
Plasmid, gag-pol gene uses the codon of the preferences in people's cell in gag-pol plasmid) and two pUC pUCs are (slowly
Auxiliary gene necessary to viral vectors is packed is located on the same plasmid, these auxiliary genes are single gene orders；Separately
One is then transgenosis plasmid).Also the slow virus packaging system for having more than four pUC pUCs is using.
Optionally, in step (4), the CD3 positive t lymphocytes are to separate to obtain from source of people peripheral blood mononuclear cells
.
Optionally, the source of people peripheral blood mononuclear cells derives from autologous vein blood, autologous bone marrow, Cord blood and placenta
Blood etc..
Still optionally further, the fresh peripheral acquired after cancer patient's operation one month, after chemicotherapy one month
Blood or marrow.
Specifically, the acquisition process of the CD3 positive t lymphocytes is as follows: into peripheral blood mononuclear cells by certain
CD3/CD28 immunomagnetic beads are added in ratio, after being incubated for a period of time, are put into magnet and are screened, it is coated to obtain immunomagnetic beads
CD3 positive t lymphocytes after removing magnetic bead, obtain CD3 positive t lymphocytes.
6th aspect, the present invention provides a kind of CAR-EGFR as described in relation to the first aspect, as described in second aspect or
The Chimeric antigen receptor T cell of targeting EGFR made from preparation method as described in terms of the 5th, the weight as described in the third aspect
Group viral vectors or host cell the answering in the drug for preparing prevention, diagnosing and treating malignant tumour as described in fourth aspect
With.Specifically, can be used for preventing, the tables such as diagnosing and treating kinds of tumors or cancer, including glioma, cancer of pancreas and lung cancer
Up to the cancer cell for having EGFR；It is suitable for the solid tumor cell or tissue of the EGFR positive simultaneously.
The application specifically: provide a kind of kit, the kit includes targeting EGFR described in first aspect
Chimeric antigen receptor, the Chimeric antigen receptor T cell of targeting EGFR as described in second aspect, the weight as described in the third aspect
One of group viral vectors, host cell as described in fourth aspect are a variety of.
Beneficial effects of the present invention:
The Chimeric antigen receptor T cell of targeting EGFR provided by the invention can promote T cell with the targeting EGFR of specificity
In the amplification of patient's body, killing tumor cell that can be efficient and specific, while EGFR wide expression in tumour cell,
And expressed in ordinary cells it is very faint, therefore the Chimeric antigen receptor T cell of targeting EGFR can specificity combination EGFR
Positive tumor cell generates fragmentation effect to EGFR positive tumor cell, not will cause damage to normal cell.
Detailed description of the invention
Fig. 1 is the plasmid map of pWPXLd-CAR-EGFR recombinant plasmid provided in an embodiment of the present invention.
Specific embodiment
The following is a preferred embodiment of the present invention, it is noted that for those skilled in the art
For, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also considered as
Protection scope of the present invention.
Embodiment one
A kind of preparation method of the Chimeric antigen receptor T cell of targeting EGFR, comprising the following steps:
(1) gene order of the Chimeric antigen receptor CAR-EGFR of targeting EGFR is prepared
The coding gene sequence of the Chimeric antigen receptor CAR-EGFR of targeting EGFR, institute are prepared by the method for PCR
The encoding gene for stating CAR-EGFR includes the nucleotide sequence as shown in SEQ ID NO:3；
(2) pWPXLd-CAR-EGFR recombinant plasmid is constructed
The encoding gene of CAR-EGFR is inserted between I restriction enzyme site of BamH I and EcoR of pWPXLD carrier, and
After pWPXLD carrier EF1 α, using EF1 α as promoter.When the encoding gene of the CAR-EGFR is inserted into pWPXLD carrier, institute
5 ' end additions initiation codon (such as ATG) for stating the encoding gene of CAR-EGFR and I restriction enzyme site phase of BamH in pWPXLD carrier
Even, 3 ' ends are also connected added with terminator codon (such as TAA) with I restriction enzyme site of EcoR in pWPXLD carrier.Then it is transferred to large intestine
Bacillus competent cell DH5 α carries out positive colony PCR identification and sequencing identification.By PCR product detected through gel electrophoresis and survey
Sequence identification meets target fragment size and sequence, successfully constructs pWPXLd-CAR-EGFR recombinant plasmid, is as shown in Figure 1
PWPXLd-CAR-EGFR recombinant plasmid.
(3) recombinant slow virus constructs
PWPXLd-CAR-EGFR recombinant plasmid, packaging plasmid psPAX2, envelope plasmid pMD2G three cotransfection are entered into training
The HEK293T cell supported.48h harvest is protected in -80 DEG C of ultra low temperature freezers containing the supernatant of virus through 0.45 μm of membrane filtration
It deposits；Supernatant of the 72h aftercrop containing virus, 0.45 μm of membrane filtration merge with the viral supernatants of 48h harvest and are added together
It in ultracentrifugation pipe, is put into Beckman ultracentrifuge one by one, setting parameter of noncentricity is 25000rpm, and centrifugation time is
2h, centrifuging temperature are controlled at 4 DEG C；It after centrifugation, discards supernatant, removal as far as possible remains in the liquid on tube wall, and virus is added
Liquid is saved, gently piping and druming is resuspended repeatedly；Through after completely dissolution, high speed centrifugation 10000rpm takes supernatant fluorescence method after being centrifuged 5min
Measuring titre, virus is according to 100 μ l, and 2 × 108A/ml packing, is stored in -80 DEG C of ultra low temperature freezers, obtains recombinant slow virus.
(4) preparation of the Chimeric antigen receptor T cell of targeting EGFR
A) separation of PBMC (peripheral blood mononuclear cells)
PBMC is from autologous vein blood, autologous bone marrow, Cord blood and placental blood etc..Preferably derive from cancer patient's hand
The fresh peripheral blood or marrow acquired after art one month, after chemicotherapy one month.
Extract patient blood, sample presentation to blood separating chamber；Peripheral blood mononuclear cells is acquired, is taken after Ficoll centrifuge separation
Intermediate layer cell；After PBS is washed, PBMC is obtained.
B) immunomagnetic beads antigenspecific T lymphocyte
Above-mentioned PBMC is taken, the basal medium for being free of serum is added, is made into cell suspension；Ratio in magnetic bead and cell is
3:1, is added CD3/CD28 immunomagnetic beads, and room temperature incubates 1-2h；The cell for being incubated for magnetic bead is screened using magnet；PBS is washed
It washs, after removing immunomagnetic beads, obtains CD3 positive t lymphocytes.
C) virus transfection method prepares antigenspecific T lymphocyte
The above-mentioned CD3 positive t lymphocytes obtained by magnetic activated cell seperation are taken, are added and CD3 positive cell number phase
The recombinant slow virus for the virus titer answered is cultivated.
The 3rd day of culture carries out cell count and changes liquid, and adjustment cell concentration is 1 × 106A/ml is inoculated with, culture；Training
Cell state is observed in feeding the 5th day, if cell density increases, diluting cells concentration is 1 × 106A/ml detects cell
Activity continues to cultivate.Amplification cultivation collected cell, and obtained the Chimeric antigen receptor T cell of targeting EGFR by the 9-11 days, and
It is stored in and feeds back in dedicated cells frozen storing liquid.
Effect example
Effect example one assesses the tumor cell in vitro killing situation of the Chimeric antigen receptor T cell of targeting EGFR
By by the Chimeric antigen receptor T cell (being abbreviated as CAR-T-EGFR) of targeting EGFR made from the method for the present invention with
The Vitro Tumor fragmentation effect of T lymphocyte (negative control group) without preparation is compared, specific: in vitro by 105
A effector cell's (CAR-T-EGFR or T lymphocyte without preparation) and target cell (U251 neuroglia cell of human oncocyte)
Quantity ratio is 1:10,1:3,1:1,3:1 and 10:1 ratio, at 37 DEG C, 5%CO2Under co-cultured, after incubation
15-18 hours, cell is collected, carries out streaming dyeing, detects cell killing situation, the results showed that method preparation of the present invention
The Chimeric antigen receptor T cell tumor-killing effect of targeting EGFR be significantly larger than negative control group, therefore through the method for the present invention
The Chimeric antigen receptor T cell of the targeting EGFR of preparation has strong tumor-killing ability.
Effect example two assesses the mouse interior tumor cell killing feelings of the Chimeric antigen receptor T cell of targeting EGFR
Condition
By the Chimeric antigen receptor T cell (CAR-T-EGFR) of the targeting EGFR by the method for the present invention preparation, without system
Standby T lymphocyte (negative control group) and physiological saline (blank control group) gives every mouse in mouse tumor model
Tail vein injection 1 × 106A cell (n=9), obtains the survivorship curve of mouse, the results showed that the targeting prepared by this method
The Chimeric antigen receptor T cell of EGFR is dead caused by capable of preferably protecting mice against because of tumour, and effect is right better than negative
According to group and blank group.
The embodiments described above only express several embodiments of the present invention, and the description thereof is more specific and detailed, but simultaneously
Limitations on the scope of the patent of the present invention therefore cannot be interpreted as.It should be pointed out that for those of ordinary skill in the art
For, without departing from the inventive concept of the premise, various modifications and improvements can be made, these belong to guarantor of the invention
Protect range.Therefore, the scope of protection of the patent of the invention shall be subject to the appended claims.
Sequence table
<110>Shenzhen Xianjin Technology Academe
<120>a kind of Chimeric antigen receptor of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application
<160> 6
<170> SIPOSequenceListing 1.0
<210> 1
<211> 465
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 1
Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
1 5 10 15
Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly Gly Thr Phe Ser
20 25 30
Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
35 40 45
Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala Asn Tyr Ala Gln
50 55 60
Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr
65 70 75 80
Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr
85 90 95
Tyr Cys Ala Arg Thr Arg Leu Lys His Gln Trp Gly Gln Gly Thr Leu
100 105 110
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
115 120 125
Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro Ala Val Ser Val
130 135 140
Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly Asp Ser Leu Arg
145 150 155 160
Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Val
165 170 175
Leu Val Ile Tyr Gly Lys Asn Asn Arg Pro Ser Gly Ile Pro Asp Arg
180 185 190
Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu Thr Ile Thr Gly
195 200 205
Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn Ser Arg Asp Ser
210 215 220
Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly Ala
225 230 235 240
Ala Ala Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr Pro Ala Pro Thr
245 250 255
Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala Cys Arg Pro Ala
260 265 270
Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe Ala Cys Asp Ile
275 280 285
Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val Leu Leu Leu Ser
290 295 300
Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys Lys Leu Leu Tyr
305 310 315 320
Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr Thr Gln Glu Glu
325 330 335
Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu Gly Gly Cys Glu
340 345 350
Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro Ala Tyr Lys Gln
355 360 365
Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly Arg Arg Glu Glu
370 375 380
Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro Glu Met Gly Gly
385 390 395 400
Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr Asn Glu Leu Gln
405 410 415
Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly Met Lys Gly Glu
420 425 430
Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln Gly Leu Ser Thr
435 440 445
Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln Ala Leu Pro Pro
450 455 460
Arg
465
<210> 2
<211> 1395
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 2
atggcccagg tgcagctggt gcagtctggg gctgaggtga agaagcctgg gtcctcggtg 60
aaggtctcct gcaaggcttc tggaggcacc ttcagcagct atgctatcag ctgggtgcga 120
caggcccctg gacaagggct tgagtggatg ggagggatca tccctatctt tggtacagca 180
aactacgcac agaagttcca gggcagagtc acgattaccg cggacgaatc cacgagcaca 240
gcctacatgg agctgagcag cctgagatct gaggacacgg ccgtgtatta ctgtgcaaga 300
actcggctta agcatcagtg gggccaaggt accctggtca ccgtctcgag tggtggaggc 360
ggttcaggcg gaggtggctc tggcggtagt gcactttctt ctgagctgac tcaggaccct 420
gctgtgtctg tggccttggg acagacagtc aggatcacat gccaaggaga cagcctcaga 480
agctattatg caagctggta ccagcagaag ccaggacagg cccctgtact tgtcatctat 540
ggtaaaaaca accggccctc agggatccca gaccgattct ctggctccag ctcaggaaac 600
acagcttcct tgaccatcac tggggctcag gcggaagatg aggctgacta ttactgtaac 660
tcccgggaca gcagtggtcc ggtattcggc ggagggacca agctgaccgt cctaggtgcg 720
gccgcaacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag 780
cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg 840
gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc 900
cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat 960
atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc 1020
tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc 1080
gcagacgccc ccgcgtacaa gcagggccag aaccagctct ataacgagct caatctagga 1140
cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga 1200
aagccgagaa ggaagaaccc tcaggaaggc ctgtacaatg aactgcagaa agataagatg 1260
gcggaggcct acagtgagat tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat 1320
ggcctttacc agggtctcag tacagccacc aaggacacct acgacgccct tcacatgcag 1380
gccctgcccc ctcgc 1395
<210> 3
<211> 1455
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 3
gccctgcctg tgacagccct gctgctgcct ctggctctgc tgctgcatgc cgctagaccc 60
atggcccagg tgcagctggt gcagtctggg gctgaggtga agaagcctgg gtcctcggtg 120
aaggtctcct gcaaggcttc tggaggcacc ttcagcagct atgctatcag ctgggtgcga 180
caggcccctg gacaagggct tgagtggatg ggagggatca tccctatctt tggtacagca 240
aactacgcac agaagttcca gggcagagtc acgattaccg cggacgaatc cacgagcaca 300
gcctacatgg agctgagcag cctgagatct gaggacacgg ccgtgtatta ctgtgcaaga 360
actcggctta agcatcagtg gggccaaggt accctggtca ccgtctcgag tggtggaggc 420
ggttcaggcg gaggtggctc tggcggtagt gcactttctt ctgagctgac tcaggaccct 480
gctgtgtctg tggccttggg acagacagtc aggatcacat gccaaggaga cagcctcaga 540
agctattatg caagctggta ccagcagaag ccaggacagg cccctgtact tgtcatctat 600
ggtaaaaaca accggccctc agggatccca gaccgattct ctggctccag ctcaggaaac 660
acagcttcct tgaccatcac tggggctcag gcggaagatg aggctgacta ttactgtaac 720
tcccgggaca gcagtggtcc ggtattcggc ggagggacca agctgaccgt cctaggtgcg 780
gccgcaacca cgacgccagc gccgcgacca ccaacaccgg cgcccaccat cgcgtcgcag 840
cccctgtccc tgcgcccaga ggcgtgccgg ccagcggcgg ggggcgcagt gcacacgagg 900
gggctggact tcgcctgtga tatctacatc tgggcgccct tggccgggac ttgtggggtc 960
cttctcctgt cactggttat caccctttac tgcaaacggg gcagaaagaa actcctgtat 1020
atattcaaac aaccatttat gagaccagta caaactactc aagaggaaga tggctgtagc 1080
tgccgatttc cagaagaaga agaaggagga tgtgaactga gagtgaagtt cagcaggagc 1140
gcagacgccc ccgcgtacaa gcagggccag aaccagctct ataacgagct caatctagga 1200
cgaagagagg agtacgatgt tttggacaag agacgtggcc gggaccctga gatgggggga 1260
aagccgagaa ggaagaaccc tcaggaaggc ctgtacaatg aactgcagaa agataagatg 1320
gcggaggcct acagtgagat tgggatgaaa ggcgagcgcc ggaggggcaa ggggcacgat 1380
ggcctttacc agggtctcag tacagccacc aaggacacct acgacgccct tcacatgcag 1440
gccctgcccc ctcgc 1455
<210> 4
<211> 485
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 4
Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His
1 5 10 15
Ala Ala Arg Pro Met Ala Gln Val Gln Leu Val Gln Ser Gly Ala Glu
20 25 30
Val Lys Lys Pro Gly Ser Ser Val Lys Val Ser Cys Lys Ala Ser Gly
35 40 45
Gly Thr Phe Ser Ser Tyr Ala Ile Ser Trp Val Arg Gln Ala Pro Gly
50 55 60
Gln Gly Leu Glu Trp Met Gly Gly Ile Ile Pro Ile Phe Gly Thr Ala
65 70 75 80
Asn Tyr Ala Gln Lys Phe Gln Gly Arg Val Thr Ile Thr Ala Asp Glu
85 90 95
Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp
100 105 110
Thr Ala Val Tyr Tyr Cys Ala Arg Thr Arg Leu Lys His Gln Trp Gly
115 120 125
Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
130 135 140
Gly Gly Ser Gly Gly Ser Ala Leu Ser Ser Glu Leu Thr Gln Asp Pro
145 150 155 160
Ala Val Ser Val Ala Leu Gly Gln Thr Val Arg Ile Thr Cys Gln Gly
165 170 175
Asp Ser Leu Arg Ser Tyr Tyr Ala Ser Trp Tyr Gln Gln Lys Pro Gly
180 185 190
Gln Ala Pro Val Leu Val Ile Tyr Gly Lys Asn Asn Arg Pro Ser Gly
195 200 205
Ile Pro Asp Arg Phe Ser Gly Ser Ser Ser Gly Asn Thr Ala Ser Leu
210 215 220
Thr Ile Thr Gly Ala Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Asn
225 230 235 240
Ser Arg Asp Ser Ser Gly Pro Val Phe Gly Gly Gly Thr Lys Leu Thr
245 250 255
Val Leu Gly Ala Ala Ala Thr Thr Thr Pro Ala Pro Arg Pro Pro Thr
260 265 270
Pro Ala Pro Thr Ile Ala Ser Gln Pro Leu Ser Leu Arg Pro Glu Ala
275 280 285
Cys Arg Pro Ala Ala Gly Gly Ala Val His Thr Arg Gly Leu Asp Phe
290 295 300
Ala Cys Asp Ile Tyr Ile Trp Ala Pro Leu Ala Gly Thr Cys Gly Val
305 310 315 320
Leu Leu Leu Ser Leu Val Ile Thr Leu Tyr Cys Lys Arg Gly Arg Lys
325 330 335
Lys Leu Leu Tyr Ile Phe Lys Gln Pro Phe Met Arg Pro Val Gln Thr
340 345 350
Thr Gln Glu Glu Asp Gly Cys Ser Cys Arg Phe Pro Glu Glu Glu Glu
355 360 365
Gly Gly Cys Glu Leu Arg Val Lys Phe Ser Arg Ser Ala Asp Ala Pro
370 375 380
Ala Tyr Lys Gln Gly Gln Asn Gln Leu Tyr Asn Glu Leu Asn Leu Gly
385 390 395 400
Arg Arg Glu Glu Tyr Asp Val Leu Asp Lys Arg Arg Gly Arg Asp Pro
405 410 415
Glu Met Gly Gly Lys Pro Arg Arg Lys Asn Pro Gln Glu Gly Leu Tyr
420 425 430
Asn Glu Leu Gln Lys Asp Lys Met Ala Glu Ala Tyr Ser Glu Ile Gly
435 440 445
Met Lys Gly Glu Arg Arg Arg Gly Lys Gly His Asp Gly Leu Tyr Gln
450 455 460
Gly Leu Ser Thr Ala Thr Lys Asp Thr Tyr Asp Ala Leu His Met Gln
465 470 475 480
Ala Leu Pro Pro Arg
485
<210> 5
<211> 20
<212> PRT
<213>artificial sequence (Artificial Sequence)
<400> 5
Ala Leu Pro Val Thr Ala Leu Leu Leu Pro Leu Ala Leu Leu Leu His
1 5 10 15
Ala Ala Arg Pro
20
<210> 6
<211> 60
<212> DNA
<213>artificial sequence (Artificial Sequence)
<400> 6
gccctgcctg tgacagccct gctgctgcct ctggctctgc tgctgcatgc cgctagaccc 60
Claims (10)
1. a kind of Chimeric antigen receptor of targeting EGFR, which is characterized in that the Chimeric antigen receptor CAR- of the targeting EGFR
EGFR includes the amino acid sequence as shown in SEQ ID NO:1.
2. the Chimeric antigen receptor of targeting EGFR as described in claim 1, which is characterized in that the inosculating antibody of the targeting EGFR
The encoding gene of original receptor CAR-EGFR includes the nucleotide sequence as shown in SEQ ID NO:2.
3. a kind of Chimeric antigen receptor T cell of targeting EGFR, which is characterized in that the Chimeric antigen receptor including targeting EGFR
CAR-EGFR, the CAR-EGFR include the amino acid sequence as shown in SEQ ID NO:1.
4. the Chimeric antigen receptor T cell of targeting EGFR as claimed in claim 3, which is characterized in that the CAR-EGFR's
Amino acid sequence includes the nucleotide sequence as shown in SEQ ID NO:2.
5. a kind of recombinant viral vector, which is characterized in that the recombinant viral vector includes as described in claim any one of 3-4
Targeting EGFR Chimeric antigen receptor T cell CAR-EGFR encoding gene.
6. recombinant viral vector as claimed in claim 5, which is characterized in that the encoding gene of the CAR-EGFR includes such as
Nucleotide sequence shown in SEQ ID NO:3.
7. a kind of host cell, which is characterized in that the host cell includes such as the described in any item recombination diseases of claim 5-6
Poisonous carrier.
8. a kind of preparation method of the Chimeric antigen receptor T cell of targeting EGFR characterized by comprising
(1) encoding gene of the Chimeric antigen receptor CAR-EGFR of targeting EGFR, the encoding gene packet of the CAR-EGFR are provided
Include nucleotide sequence corresponding to the amino acid sequence as shown in SEQ ID NO:1；
(2) encoding gene of the CAR-EGFR is inserted into pWPXLD carrier, obtains pWPXLD-CAR-EGFR recombination matter
Grain；
(3) by the pWPXLD-CAR-EGFR recombinant plasmid and envelope plasmid, packaging plasmid cotransfection host cell, weight is obtained
Group slow virus；
(4) recombinant slow virus is infected into CD3 positive t lymphocytes, obtains the Chimeric antigen receptor T cell of targeting EGFR.
9. the preparation method of the Chimeric antigen receptor T cell of targeting EGFR as claimed in claim 8, which is characterized in that described
The encoding gene of CAR-EGFR includes the nucleotide sequence as shown in SEQ ID NO:3.
10. a kind of Chimeric antigen receptor CAR-EGFR such as the described in any item targeting EGFRs of claim 1-2, such as claim
3-4 is described in any item or preparation method as described in claim 8-9 made from targeting EGFR Chimeric antigen receptor T it is thin
It is prepared by born of the same parents or such as the described in any item recombinant viral vectors of claim 5-6 or host cell as claimed in claim 7
Prevent, the application in the drug of diagnosing and treating malignant tumour.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810513550.1A CN110526985A (en) | 2018-05-25 | 2018-05-25 | A kind of Chimeric antigen receptor of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810513550.1A CN110526985A (en) | 2018-05-25 | 2018-05-25 | A kind of Chimeric antigen receptor of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110526985A true CN110526985A (en) | 2019-12-03 |
Family
ID=68656785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810513550.1A Withdrawn CN110526985A (en) | 2018-05-25 | 2018-05-25 | A kind of Chimeric antigen receptor of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110526985A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114437229A (en) * | 2020-11-01 | 2022-05-06 | 复旦大学 | Preparation and use of CAR T immune cells carrying PD-1 chain antibody and targeting EGFR antigen |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160627A1 (en) * | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| WO2015084513A1 (en) * | 2013-12-06 | 2015-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| CN105920592A (en) * | 2015-09-11 | 2016-09-07 | 中国人民解放军总医院 | Application of CARHER1-NKT cells in preparation of preparations for treatment of HER1 positive lung cancer in progressive stage |
-
2018
- 2018-05-25 CN CN201810513550.1A patent/CN110526985A/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014160627A1 (en) * | 2013-03-25 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-cd276 polypeptides, proteins, and chimeric antigen receptors |
| WO2015084513A1 (en) * | 2013-12-06 | 2015-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Thymic stromal lymphopoietin receptor-specific chimeric antigen receptors and methods using same |
| CN105920592A (en) * | 2015-09-11 | 2016-09-07 | 中国人民解放军总医院 | Application of CARHER1-NKT cells in preparation of preparations for treatment of HER1 positive lung cancer in progressive stage |
Non-Patent Citations (2)
| Title |
|---|
| GENBANK: "anti-epidermal growth factor receptor scFv, partial [synthetic construct]", 《GENBANK》 * |
| 孙梦梅: "抗EGFR人源化抗体的构建、表达、纯化和功能分析", 《中国学位论文全文数据库》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114437229A (en) * | 2020-11-01 | 2022-05-06 | 复旦大学 | Preparation and use of CAR T immune cells carrying PD-1 chain antibody and targeting EGFR antigen |
| CN114437229B (en) * | 2020-11-01 | 2024-03-12 | 复旦大学 | Preparation and application of CAR T immune cells carrying PD-1 chain antibody and targeting EGFR antigen |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110144326A (en) | A kind of antitumor T cell of targeting and its preparation method and application | |
| CN109836496A (en) | It is a kind of to target the single-chain antibody of CD317, Chimeric antigen receptor T cell and its preparation method and application | |
| CN109836497A (en) | A kind of single-chain antibody of targeting EGFR, Chimeric antigen receptor T cell and its preparation method and application | |
| CN109836495A (en) | It is a kind of to target the single-chain antibody of CD22, Chimeric antigen receptor T cell and its preparation method and application | |
| CN110144328A (en) | A kind of antitumor T cell of targeting and its preparation method and application | |
| CN110526970A (en) | Target single-chain antibody, the Chimeric antigen receptor T cell and its preparation method and application of CD133 | |
| CN109957018A (en) | It is a kind of to target the single-chain antibody of CD22, Chimeric antigen receptor T cell and its preparation method and application | |
| CN109836493A (en) | It is a kind of to target the single-chain antibody of CD19, Chimeric antigen receptor T cell and its preparation method and application | |
| CN110157676A (en) | A kind of targeting T lymphocyte and its preparation method and application | |
| CN110526976A (en) | It is a kind of to target the single-chain antibody of PSMA, Chimeric antigen receptor T cell and its preparation method and application | |
| CN110526987A (en) | Target Chimeric antigen receptor, the Chimeric antigen receptor T cell and its preparation method and application of CD133 | |
| CN109957546A (en) | A kind of Chimeric antigen receptor T cell and its preparation method and application targeting CD317 | |
| CN110526979A (en) | Target single-chain antibody, the Chimeric antigen receptor T cell and its preparation method and application of FAP | |
| CN110157675A (en) | A kind of targeting T lymphocyte and its preparation method and application | |
| CN109957025A (en) | It is a kind of to target the single-chain antibody of DR5, Chimeric antigen receptor T cell and its preparation method and application | |
| CN110157677A (en) | A kind of targeting T lymphocyte and its preparation method and application | |
| CN109957023A (en) | It is a kind of to target the single-chain antibody of CD22, Chimeric antigen receptor T cell and its preparation method and application | |
| CN109957020A (en) | It is a kind of to target the single-chain antibody of DR5, Chimeric antigen receptor T cell and its preparation method and application | |
| CN109837303A (en) | A kind of Chimeric antigen receptor T cell and its preparation method and application for the targeting CD317 knocking out PD1 | |
| CN110144327A (en) | A kind of antitumor T cell of targeting and its preparation method and application | |
| CN110526977A (en) | It is a kind of to target the single-chain antibody of MUC1, Chimeric antigen receptor T cell and its preparation method and application | |
| CN110526974A (en) | It is a kind of to target the single-chain antibody of MUC16, Chimeric antigen receptor T cell and its preparation method and application | |
| CN110527667A (en) | A kind of Chimeric antigen receptor and Chimeric antigen receptor T cell and its preparation method and application targeting MUC16 | |
| CN110526988A (en) | A kind of Chimeric antigen receptor and Chimeric antigen receptor T cell and its preparation method and application targeting MUC1 | |
| CN109836500A (en) | It is a kind of to target the single-chain antibody of DR5, Chimeric antigen receptor T cell and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20191203 |
|
| WW01 | Invention patent application withdrawn after publication |